Description
Acelarin is a DNA synthesis inhibitor with EC50 of 0.2 nM. Acelarin is a prodrug based on an aryloxy phosphoramidate derivative of gemcitabine. It is converted into the active metabolites dFdCDP and dFdCTP. dFdCDP can inhibit ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP can be incorporated into DNA, resulting in premature termination of DNA replication and eventually induction of apoptosis. Phase III clinical trials for the treatment of Pancreatic cancer are on-going